Dafni Moschidou
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 09, 2024
Counteracting bone fragility with human amniotic mesenchymal stem cells.
Journal: Scientific reports
Published: October 03, 2016
Human Amniocytes Are Receptive to Chemically Induced Reprogramming to Pluripotency.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 18, 2016
Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome.
Journal: Stem cells and development
Published: January 06, 2016
Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta.
Journal: Stem cells and development
Published: September 14, 2013
Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta.
Journal: Stem cells translational medicine
Published: December 01, 2012
Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics.
Journal: Stem cells and development
Published: October 12, 2012
Molecular signature of human amniotic fluid stem cells during fetal development.
Journal: Current stem cell research & therapy
Published: July 20, 2012
Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 05, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026